Pharmaceutical Industry Trends | Healthcare Trends

Construct winning strategies that anticipate where value will lie. In Vivo’s in-depth analysis spans influential deals, R&D, commercial and market access strategies.

How it helps

With In Vivo, you’ll benefit from:

Insight about the key players in the industry
In-depth coverage of company strategies
Expert analysis of deal making, R&D, commercial, market access and finance strategies and trends
Exclusive insider insight and thought leadership
Help with specific questions from our renowned Ask-the-Analyst™ service

How it works
Access mission-critical information via a simple-to-use interface. And if you need to need to find out more about developments or pharmaceutical industry trends to support presentations, proposals or business-critical decisions, you can access our worldwide network of expert analysts through our acclaimed Ask-the-Analyst™ service.

Plus, you can identify threats and opportunities using our Execs on the Move feature, which tracks the company movements of senior executives.

Start a free trial

In Vivo

Medtechs Enter The Decade of Digital, Consumers and Wellness

By Ashley Yeo 11 Dec 2019

For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

In Vivo

Critical Insights into Market Access

10 Dec 2019

Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.

In Vivo

Brexit To And Fro Continues Into Fresh Decade

By Ian Schofield 06 Dec 2019

Three Brexit deadlines have come and gone, and the UK is still a member of the European Union. It will remain so until it agrees a withdrawal deal or leaves without one at the end of January 2020. Alternatively, it could secure yet another extension to the Article 50 period beyond January 31. Or it could decide not to leave at all.

In Vivo

From US To EU: Young Biotechs Going It Alone

By Jo Shorthouse 28 Nov 2019

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

In Vivo

MHealth And Research In Oncology

By Niharika Dandamudi 20 Nov 2019

The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices.”

In Vivo

How Proximity Creates Partnerships

By William Looney 08 Nov 2019

Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.

In Vivo

GSK's Hal Barron On R&D Progress At Two-Year Mark

By Andrew McConaghie 01 Nov 2019

Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.

In Vivo

In Vivo Personalised Medicine

18 Sep 2019

With more individualized treatments, such as cell and gene therapies, coming to market every day, In Vivo can keep you up to date on the diversity within clinical R&D, trials, the latest trends and the barriers that still exist within personalised medicine. We’ve pulled together a helpful infographic to summaries these changes.

In Vivo

Personalised Medicine: Treating the individual patient

17 Sep 2019

In Vivo

Six of the Greatest Therapeutic R&D Challenges

23 Aug 2019

Explore the six biggest therapeutic R&D challenges facing the industry today with a free infographic from In Vivo. This snapshot view of the major issues facing R&D is packed with data and insights about everything from drug resistance to diagnostics challenges.

In Vivo

In Vivo Content - Relied Upon by Senior Decision Makers

21 Aug 2019

There are many ways to market your brand and establish your business as a thought leader - but none of these methods compare to the distinct advantage gained through marketing with In Vivo and Informa Pharma Intelligence. The articles, news and interviews we feature are used daily by senior decision-makers to support their decisions, and to keep abreast of what their competitors are doing.

In Vivo

MedTech Forum 2019: The Future Is Here But Industry Still Needs A Long-Term Vision

By Ashley Yeo 16 Aug 2019

In a world where national economies are beset by conflicting spending priorities, health care is oftentimes too low on the agenda, health care observers say. One of these is Boston Scientific senior vice-president Eric Thépaut, who understands the dilemmas, but says that health care will soon force its way up the priority list. He has advice for future-ready medtech innovators.

In Vivo

Could The Gut Cure Brain Disease?

By Melanie Senior 08 Aug 2019

Scientists now understand that there are multiple, bi-directional links between gut and brain. They are using this knowledge to develop new treatments for some of the most challenging chronic conditions, including Alzheimer’s disease, Parkinson’s disease and obesity.

In Vivo

Meet the 2019 Titans of Pharma

31 Jul 2019

Get exclusive info on the leaders of the Pharma industry.The 2019 Titan of Pharma infographic is a snapshot of the industry’s top leaders and the businesses they oversee.

In Vivo

How To Negotiate With Public Payers: Five Lessons - And A Few Cautions - From The UK's New Pact On Drug Price And Access

By William Looney 30 Jul 2019

In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets.

In Vivo: strategic insights for life sciences decision-makers

Strategic industry insight

What's included

Below are the feature list

Cutting edge thought leadership

Expert analysis

Hear from news makers

Ask the expert

In depth examination of deal-making and finance strategies

Pharma Intelligence: latest

Latest headlines

Meet the team

Below are the Analyst Profile

William Looney

Editor, Executive Editor, In Vivo

Cathy Kelly

Editor, Senior editor

Denise Peterson

Management, Editor In Chief, Pharma US

Related Products

Datamonitor Healthcare: data analysis and insight

Medtech Insight: global medical technology news & analysis

Meddevicetracker: medical device intelligence and forecasts

Next steps

This is Contactus Section

Request a Trial

How can we help you?

Pharma Report Store